• 1
    Thompson, I. M., Jr., C. M. Tangen, J. Paradelo, M. S. Lucia, G. Miller, D. Troyer, et al. 2006. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA 296:23292335.
  • 2
    Wiegel, T., D. Bottke, U. Steiner, A. Siegmann, R. Golz, S. Storkel, et al. 2009. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J. Clin. Oncol. 27:29242930.
  • 3
    Bolla, M., H. van Poppel, L. Collette, P. van Cangh, K. Vekemans, and L. D. Pozzo. 2005. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 366:572578.
  • 4
    Thompson, I. M., C. M. Tangen, and E. A. Klein. 2009. Is there a standard of care for pathologic stage T3 prostate cancer? J. Clin. Oncol. 27:28982899.
  • 5
    Nielsen, M. E., B. J. Trock, and P. C. Walsh. 2010. Salvage or adjuvant radiation therapy: counseling patients on the benefits. J. Natl. Compr. Canc. Netw. 8:228237.
  • 6
    Showalter, T. N., N. Ohri, K. G. Teti, K. A. Foley, S. W. Keith, E. J. Trabulsi, et al. 2011. Physician beliefs and practices for adjuvant and salvage radiation therapy after prostatectomy. Int. J. Radiat. Oncol. Biol. Phys. 82:e233e238.
  • 7
    Trock, B. J., M. Han, S. J. Freedland, E. B. Humphreys, T. L. DeWeese, A. W. Partin, et al. 2008. Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA 299:27602769.
  • 8
    Swanson, G. P., M. A. Hussey, C. M. Tangen, J. Chin, and E. Messing. 2007. Predominant treatment failure pattern in postprostatectomy patients is local: analysis of patterns of treatment failure in SWOG 8794. J. Clin. Oncol. 25:22252229.
  • 9
    Michalski, J. M., C. Lawton, I. E. Naqa, M. Ritter, E. O'Meara, M. J. Seider, et al. 2010. Development of RTOG consensus guidelines for the definition of the clinical target volume for postoperative conformal radiation therapy for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 76:361368.
  • 10
    Harrison, A., M. Studenski, A. Harvey, E. J. Trabulsi, Y. Xiao, Y. Yu, et al. 2011. Potential for dose-escalation in the postprostatectomy setting with intensity-modulated radiation therapy: a dosimetric study using EORTC consensus guidelines for target volume contours. Pract. Radiat. Oncol. 1:105114.
  • 11
    Koontz, B. F., S. Das, K. Temple, S. Bynum, S. Catalano, J. I. Koontz, et al. 2009. Dosimetric and radiobiologic comparison of 3D conformal versus intensity modulated planning techniques for prostate bed radiotherapy. Med. Dosim. 34:256260.
  • 12
    Nguyen, P. L., X. Gu, S. R. Lipsitz, T. K. Choueiri, W. W. Choi, Y. Lei, et al. 2011. Cost implications of the rapid adoption of newer technologies for treating prostate cancer. J. Clin. Oncol. 291:15171524.
  • 13
    Ost, P., V. Fonteyne, G. Villeirs, N. Lumen, W. Oosterlinck, and G. De Meerleer. 2009. Adjuvant high-dose intensity-modulated radiotherapy after radical prostatectomy for prostate cancer: clinical results in 104 patients. Eur. Urol. 56:669677.
  • 14
    Bastasch, M. D., B. S. Teh, W.-Y. Mai, L. S. Carpter, H. H. Lu, J. K. Chiu, et al. 2002. Post-nerve sparing prostatectomy, dose-escalated intensity-modulated radiotherapy: effect on erectile function. Int. J. Radiat. Oncol. Biol. Phys. 54:101106.
  • 15
    Bekelman, J. E., N. Mitra, J. A. Efstathiou, K. Liao, R. Sunderland, D. N. Yeboa, et al. 2011. Outcomes after intensity-modulated versus conformal radiotherapy in older men with nonmetastatic prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 81:e325e334.
  • 16
    Sheets, N. C., G. H. Goldein, A.-M. Meyer, Y. Wu, Y. Chang, T. Stirmer, et al. 2012. Intensity-modulated radiation therapy, proton therapy, or conformal radiation therapy and morbidity and disease control in localized prostate cancer. JAMA 307:16111620.
  • 17
    Warren, J. L., C. N. Klabunde, D. Schrag, P. B. Bach, and G. F. Riley. 2002. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med. Care 40(8 Suppl.):IV-3IV-18.
  • 18
    Hu, J. C., X. Gu, S. R. Lipsitz, M. J. Barry, A. V. D'Amico, A. C. Weinberg, et al. 2009. Comparative effectiveness of minimally invasive vs open radical prostatectomy. JAMA 302:15571564.
  • 19
    Giordano, S. H., A. Lee, Y.-F. Kuo, J. Freeman, and J. S. Goodwin. 2006. Late gastrointestinal toxicity after radiation for prostate cancer. Cancer 107:423432.
  • 20
    D'Agostino, R. B., Jr. 1998. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat. Med. 17:22652281.
  • 21
    Goenka, A., J. M. Magsanoc, X. Pei, M. Schechter, M. Kollmeier, B. Cox, et al. 2011. Improved toxicity profile following high-dose postprostatectomy salvage radiation therapy with intensity-modulated radiation therapy. Eur. Urol. 60:11421148.
  • 22
    Goldin, G. H., N. C. Sheets, A.-M. Meyer, T.-M. Kuo, Y. Wu, T. Sturmer, et al. 2013. Comparative effectiveness of intensity-modulated radiotherapy and conventional conformal radiotherapy in the treatment of prostate cancer after radical prostatectomy. JAMA Intern. Med. 173:11361143.
  • 23
    Valicenti, R. K., L. G. Gomella, M. Ismail, S. G. Mulholland, R. O. Petersen, and B. W. Corn. 1998. Effect of higher radiation dose on biochemical control after radical prostatectomy for pT3N0 prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 42:501506.
  • 24
    Anscher, M. S., R. Clough, and R. Dodge. 2000. Radiotherapy for a rising prostate-specific antigen after radical prostatectomy: the first 10 years. Int. J. Radiat. Oncol. Biol. Phys. 48:369375.
  • 25
    Cheung, R., S. L. Tucker, L. Dong, R. de Crevoisier, A. K. Lee, S. Frank, et al. 2007. Investigation of bladder dose and volume factors influencing late urinary toxicity after external beam radiotherapy for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 67:10591065.
  • 26
    Viswanathan, A. N., E. D. Yorke, L. B. Marks, P. J. Eifel, and W. U. Shipley. 2010. Radiation dose-volume effects of the urinary bladder. Int. J. Radiat. Oncol. Biol. Phys. 76:S116S122.
  • 27
    Miller, D. C., J. T. Wei, R. L. Dunn, J. E. Montie, H. Pimentel, H. M. Sandler, et al. 2006. Use of medications or devices for erectile dysfunction among long-term prostate cancer treatment survivors: potential influence of sexual motivation and/or indifference. Urology 68:166171.
  • 28
    Virnig, B., J. L. Warren, G. S. Cooper, C. N. Klabunde, N. Schussler, and J. Freeman. 2002. Studying radiation therapy using SEER-Medicare-linked data. Med. Care 40(8 Suppl.):IV-49IV-54.
  • 29
    Potosky, A. L., J. L. Warren, E. R. Riedel, C. N. Klabunde, C. C. Earle, and C. B. Begg. 2002. Measuring complications of cancer treatment using the SEER-Medicare data. Med. Care 40(8 Suppl.):6268.
  • 30
    Zelefsky, M. J., M. Kollmeier, B. Cox, A. Fidaleo, D. Sperling, X. Pei, et al. 2012. Improved clinical outcomes with high-dose image guided radiotherapy compared with non-IGRT for the treatment of clinically localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 84:125129.